Drug Sales Trends for azathioprine

Payment Methods and Pharmacy Types for azathioprine (2009)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$10,629,835
INSIDE ANOTHER STORE	$6,443,692

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	276,126
INSIDE ANOTHER STORE	243,878

Revenues by Payment Method

Payment Method	Revenues
MEDICARE	$8,157,800
OTHER FEDERAL	$2,362,388

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for azathioprine

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
AZATHIOPRINE			2022
AZATHIOPRINE			2021
AZATHIOPRINE			2020
AZATHIOPRINE			2019
AZATHIOPRINE			2018
AZATHIOPRINE			2017
AZATHIOPRINE			2016

Azathioprine Market Analysis and Sales Projections, Patent Status, and Competitive Outlook

Last updated: September 7, 2026

Azathioprine is a mature, low-cost immunosuppressant with no meaningful remaining originator exclusivity. Demand is supported by organ transplantation, autoimmune disease, inflammatory bowel disease, and steroid-sparing treatment. The market is genericized, fragmented, and price-sensitive. Global azathioprine sales are likely concentrated in tablets, with limited commercial upside unless a company obtains differentiated positioning through supply reliability, specialty distribution, combination therapy, or a new formulation.

A reasonable base-case forecast places worldwide azathioprine product revenue at approximately $180 million to $230 million in 2025, rising to $190 million to $260 million by 2030. Growth is driven mainly by patient volume and transplant activity, while generic price erosion limits revenue expansion.

What is azathioprine used for?

Azathioprine is a purine antimetabolite immunosuppressant. It is converted to active thiopurine metabolites that inhibit lymphocyte proliferation. The drug is administered orally and, in some markets, is available in injectable form.

Therapeutic area	Commercial role	Demand characteristics
Organ transplantation	Maintenance immunosuppression	Stable, recurring demand; competition from tacrolimus and mycophenolate
Rheumatoid arthritis	Steroid-sparing and disease-modifying therapy	Declining relative use because of biologics and targeted therapies
Inflammatory bowel disease	Maintenance therapy, often after steroid induction	Persistent use, particularly where biologics are unaffordable
Autoimmune diseases	Lupus, autoimmune hepatitis, vasculitis, myasthenia gravis and related conditions	Specialist-driven, fragmented demand
Dermatology and other immune disorders	Off-label or guideline-supported use in selected conditions	Small but durable niche demand

The U.S. prescribing information identifies azathioprine for rejection prevention in kidney transplantation and for management of active rheumatoid arthritis in selected patients. Other uses are based on clinical practice, guidelines, and local regulatory labeling rather than a single global indication set (U.S. Food and Drug Administration [FDA], 2024).

How large is the azathioprine market?

The market is difficult to measure because azathioprine is sold by multiple generic manufacturers, wholesalers, hospital pharmacies, and national procurement systems. Public companies generally do not report azathioprine revenue separately.

Estimated global market, 2025

Segment	Estimated 2025 revenue	Market characteristics
Oral tablets	$150 million-$195 million	Core market; 25 mg and 50 mg strengths dominate
Hospital and injectable products	$10 million-$25 million	Concentrated in transplant and hospital settings
Specialty and institutional supply	$20 million-$35 million	Includes government tenders and controlled distribution
Total estimated market	$180 million-$230 million	Modeled market, not a consolidated audited figure

The largest commercial markets are expected to be the United States, Europe, Japan, China, India, Australia, and selected Latin American countries. Revenue concentration does not necessarily track patient volume. Low-income and middle-income markets may have substantial unit demand but lower average selling prices.

Main market drivers

1. Growth in the global transplant population and longer post-transplant survival.
2. Continued use in autoimmune disease where biologics are unavailable, unaffordable, or clinically unsuitable.
3. Demand for low-cost steroid-sparing therapy.
4. Procurement requirements for multiple generic suppliers to reduce shortage exposure.
5. Use in markets with limited reimbursement for biologic and targeted immunomodulator products.

Main market restraints

• Generic price competition.
• Substitution by tacrolimus, mycophenolate mofetil, mycophenolic acid, methotrexate, biologics, and targeted small molecules.
• Safety monitoring requirements.
• TPMT and NUDT15 pharmacogenetic considerations.
• Declining use in rheumatoid arthritis and some inflammatory diseases.
• Limited ability to differentiate a conventional tablet.

When does azathioprine lose exclusivity?

Azathioprine lost meaningful U.S. small-molecule exclusivity decades ago. The compound was commercialized under the Imuran brand, historically associated with GlaxoSmithKline and predecessor companies. Current U.S. products are predominantly generic.

Exclusivity category	Current status
New chemical entity exclusivity	Expired
U.S. patent exclusivity	Expired or commercially irrelevant
Pediatric exclusivity	No material current protection identified
Orphan exclusivity	No broad orphan exclusivity controlling the product
Regulatory exclusivity	No current exclusivity blocking ordinary generic competition
Biosimilar exclusivity	Not applicable; azathioprine is a small molecule

There is no credible path to restoring broad market exclusivity for the existing azathioprine molecule. Commercial protection would require a new product, such as a novel formulation, delivery system, combination, or independently patentable manufacturing process.

What patents protect azathioprine?

The original compound and core product patents are expired. Current patent risk is therefore more likely to arise from formulation, manufacturing, packaging, or use-specific claims than from the active ingredient itself.

Patent estate assessment

Patent category	Current commercial relevance	Risk level
Azathioprine compound patents	Expired	None
Conventional immediate-release tablets	Generally unprotected	None to low
Dosage-strength claims	Usually not defensible against ordinary generics	Low
Treatment-method patents	Limited practical impact because of mature clinical use	Low
Extended-release or targeted delivery	Potentially relevant if separately patented	Product-specific
Combination products	Potentially relevant	Product-specific
Manufacturing and impurity-control processes	Possible process advantage	Low to moderate
Device or specialty packaging	Limited	Low

The U.S. Orange Book should be reviewed for the specific NDA and listed patents associated with any current branded or specialty azathioprine product. Generic manufacturers should not assume that a listed patent for a modified product blocks approval of a conventional immediate-release tablet. Patent scope depends on the claims, dosage form, formulation, and regulatory filing route (FDA, 2024a).

What is the Orange Book status of azathioprine?

Azathioprine is marketed in the United States through legacy branded and generic approvals. The Orange Book remains relevant for identifying approved products, reference-listed-drug relationships, and any listed patents or exclusivities. In practice, the commercial market is dominated by abbreviated new drug applications for standard tablet products.

A generic applicant seeking approval for a conventional azathioprine tablet would generally use the reference product and demonstrate bioequivalence through the applicable abbreviated pathway. Paragraph IV certification is unlikely to create a major strategic event for ordinary azathioprine tablets because the foundational patent estate has expired.

Are there Paragraph IV challenges for azathioprine?

Paragraph IV litigation does not appear to be a central current market issue for conventional azathioprine. Any remaining challenge would likely concern a branded reformulation, new dosage form, or narrow method-of-use patent rather than the original molecule.

Challenge type	Expected relevance
Challenge to original azathioprine compound patent	None; expired
Challenge to standard tablet patent	Low
Challenge to extended-release product	Possible
Challenge to combination product	Possible
Challenge to method-of-use patent	Limited and indication-specific
ANDA approval dispute	More likely to involve labeling, bioequivalence, or manufacturing than core composition

No major active U.S. patent litigation materially controlling the standard azathioprine tablet market is evident from the mature generic profile of the product. A buyer or licensee should still conduct a current PACER, Orange Book, FDA Paragraph IV, and WIPO search before closing a transaction.

What is the competitive landscape for azathioprine?

Azathioprine competes with both low-cost immunosuppressants and higher-value specialty therapies.

Direct pharmacologic competitors

• Mycophenolate mofetil
• Mycophenolic acid
• Methotrexate
• Leflunomide
• Cyclophosphamide in selected severe autoimmune conditions
• Tacrolimus and cyclosporine in transplantation

Higher-value substitutes

• Adalimumab and other TNF inhibitors
• Ustekinumab
• Vedolizumab
• Risankizumab
• JAK inhibitors
• B-cell-directed therapies
• Calcineurin inhibitors and mTOR inhibitors in transplantation

Azathioprine retains a cost advantage. It is most exposed where treatment guidelines favor newer therapies, insurance coverage is strong, and physicians prioritize rapid or targeted immunologic control.

Azathioprine versus mycophenolate mofetil

Attribute	Azathioprine	Mycophenolate mofetil
Price	Generally lower	Low-cost generic but often higher than azathioprine
Transplant use	Established maintenance option	Often preferred in modern protocols
Monitoring	CBC, liver function, pharmacogenetic considerations	CBC and infection monitoring
Pregnancy considerations	Used selectively with specialist oversight	More restrictive reproductive safety profile
Commercial outlook	Stable niche	Larger transplant franchise
Differentiation potential	Limited	Also highly genericized

Azathioprine can remain competitive when cost, pregnancy planning, historical patient stability, or local protocol favors it. Mycophenolate is the stronger reference competitor in many transplant markets.

What formulations are protected by azathioprine patents?

The commercial baseline is the immediate-release oral tablet. Conventional 25 mg and 50 mg tablets have limited differentiation potential.

Potentially protectable products include:

• Extended-release tablets.
• Enteric-coated products intended to modify gastrointestinal exposure.
• Fixed-dose combinations with corticosteroids or other immunosuppressants.
• Pharmacogenomic dosing systems.
• Hospital-ready injectable presentations.
• Stability-enhanced products for hot or humid climates.
• Abuse-resistant or adherence-oriented packaging.
• Formulations designed to reduce gastrointestinal intolerance.

A formulation must provide a clinically or regulatory meaningful benefit to justify development. A minor excipient change without improved bioavailability, stability, tolerability, adherence, or manufacturing performance is unlikely to support durable pricing power.

How strong is the azathioprine patent estate?

The patent estate for the existing molecule is weak. The commercial strength of a new azathioprine product would depend on the product-specific claims, regulatory designation, clinical differentiation, and freedom to operate.

Evaluation factor	Assessment
Core molecule protection	Very weak; expired
Generic entry barrier	Very low
Brand pricing power	Minimal for standard tablets
Manufacturing know-how	Potentially useful but rarely exclusionary
New formulation opportunity	Moderate but technically and commercially uncertain
Method-of-use protection	Narrow and difficult to enforce in mature indications
Litigation leverage	Low for standard products
Licensing value	Limited unless linked to a differentiated formulation or regional supply position

What are azathioprine sales projections for 2025-2030?

The following projections use a bottom-up market model based on stable-to-low single-digit unit growth, continued generic price pressure, and modest expansion in transplant and autoimmune treatment volume. They represent estimated global product revenue rather than revenue for one manufacturer.

Year	Bear case	Base case	Upside case
2025	$160 million	$205 million	$240 million
2026	$158 million	$208 million	$247 million
2027	$157 million	$212 million	$255 million
2028	$156 million	$216 million	$264 million
2029	$155 million	$221 million	$274 million
2030	$154 million	$226 million	$284 million

Projection assumptions

The bear case assumes continuing price erosion, substitution by mycophenolate and biologics, and no significant new product differentiation. The base case assumes approximately 1% to 2% annual unit growth offset by low single-digit price declines. The upside case assumes stronger transplant demand, supply disruptions affecting competitors, and successful commercialization of a differentiated formulation.

The base-case compound annual growth rate is approximately 2%. This reflects a mature market where patient growth is partially offset by lower prices.

What is the revenue exposure for manufacturers?

A standard generic azathioprine portfolio is unlikely to generate high standalone revenue unless the manufacturer has scale, institutional contracts, or a broad immunosuppressant portfolio.

Manufacturer profile	Revenue opportunity	Strategic rationale
Large generic company	Moderate volume, low margin	Portfolio completeness and hospital contracting
Specialty generic company	Moderate	Potential formulation or supply differentiation
Contract manufacturer	Low direct value	Stable but price-sensitive production demand
Branded specialty company	Limited	Requires a differentiated product
Regional supplier	Attractive in selected markets	Government tenders and shortage substitution
Biotech company	Low strategic fit	No biologic platform advantage

Gross margins are likely to be higher for injectable, shortage-constrained, or institutionally contracted products than for standard tablets. Tablets remain vulnerable to tender pricing and pharmacy substitution.

What generic launch risks exist?

A new generic launch faces low legal barriers but significant commercial barriers.

Regulatory risks

• Failure to demonstrate bioequivalence.
• Product-specific dissolution variability.
• Manufacturing observations or warning letters.
• Inadequate control of impurities and degradation products.
• Labeling differences that affect substitution.
• Pharmacovigilance obligations for immunosuppression-related adverse events.

Commercial risks

• Incumbent suppliers with lower manufacturing costs.
• Small market size relative to development and registration expenses.
• Wholesaler concentration.
• Hospital formulary inertia.
• Limited ability to raise price after shortages resolve.
• Inventory write-downs from tender losses.

Clinical and safety risks

Azathioprine carries clinically important warnings involving myelosuppression, hepatotoxicity, serious infections, malignancy risk, and hypersensitivity. TPMT and NUDT15 status can influence toxicity risk. These issues do not usually prevent generic substitution, but they increase the importance of accurate labeling, patient monitoring, and pharmacovigilance (FDA, 2024; Clinical Pharmacogenetics Implementation Consortium, 2018).

Which companies are challenging azathioprine?

The market is challenged less by named patent litigants than by generic substitution and therapeutic alternatives. Generic manufacturers vary by jurisdiction and product presentation. In the United States, standard azathioprine products have historically been supplied by multiple generic companies, while branded availability has been limited relative to the original Imuran franchise.

Competitive pressure comes from:

• Generic azathioprine tablet manufacturers.
• Generic mycophenolate suppliers.
• Tacrolimus manufacturers.
• Specialty transplant-drug distributors.
• Biologic and targeted-therapy companies in autoimmune indications.

The main competitive question is not whether a company can enter the azathioprine market. It is whether it can secure sufficient volume and supply reliability to earn an acceptable return.

What is the FDA regulatory status of azathioprine?

Azathioprine is an FDA-approved small-molecule immunosuppressant. U.S. regulatory pathways include the original NDA framework and generic ANDA approvals. The drug is not a biologic, so biosimilar legislation and the Purple Book do not apply.

FDA-related commercial priorities include:

• Compliance with current good manufacturing practice requirements.
• Bioequivalence for generic products.
• Accurate warnings and contraindications.
• Pharmacovigilance for serious adverse events.
• Consistent supply for transplant patients.
• Appropriate handling of formulation or strength changes.

Does azathioprine have licensing or partnership value?

Licensing value is limited for standard azathioprine. More attractive opportunities may involve:

• Regional rights in markets with transplant growth.
• Supply agreements with hospitals or government buyers.
• A differentiated injectable product.
• A modified-release formulation.
• A pharmacogenomic dosing service linked to prescribing.
• Combination products with a defensible clinical or regulatory profile.
• Manufacturing technology that reduces cost or impurity burden.

A conventional tablet license without territorial access, guaranteed volume, or supply differentiation is unlikely to command significant upfront consideration.

What patent litigation affects azathioprine?

No major current litigation appears to control the ordinary generic azathioprine market. Litigation exposure is more likely to arise from:

1. A new formulation patent.
2. A combination-product patent.
3. A manufacturing-process dispute.
4. A contract or supply disagreement.
5. Product liability or pharmacovigilance claims.

For transaction diligence, the relevant legal review should include Orange Book listings, ANDA Paragraph IV notices, federal district court filings, Federal Circuit decisions, FDA enforcement records, and patent assignments.

Key Takeaways

• Azathioprine is a mature generic immunosuppressant with no meaningful remaining core exclusivity.
• The estimated global market is approximately $180 million to $230 million in 2025.
• Base-case global revenue is projected to reach about $226 million by 2030.
• Transplantation is the most durable demand segment.
• Autoimmune and inflammatory disease use remains important but faces substitution from biologics and targeted therapies.
• Conventional tablets have weak patent protection and low entry barriers.
• A new commercial opportunity would require formulation, supply, geographic, or service differentiation.
• Paragraph IV litigation and biosimilar competition are not major current risks for standard azathioprine.
• Generic price pressure, procurement concentration, and therapeutic substitution are the main commercial threats.
• The strongest value proposition is reliable, low-cost supply in transplant and institutional markets.

FAQs

Is azathioprine still profitable for generic manufacturers?

It can be profitable at scale, particularly with efficient manufacturing, institutional contracts, or reliable supply during competitor shortages. Standard tablet pricing limits standalone profitability.

Is azathioprine included in Medicare coverage?

Coverage depends on the product, Part D formulary, pharmacy benefit design, and indication. Generic azathioprine is generally positioned as a low-cost formulary product.

Can a company patent a new azathioprine formulation?

Yes. A new formulation may be patentable if it provides a novel and non-obvious technical or clinical benefit. The patent would not restore protection for the original molecule.

Is azathioprine a biologic or biosimilar product?

No. Azathioprine is a conventional small-molecule drug. Generic approval generally proceeds through an ANDA or a comparable national pathway, not a biosimilar application.

What is the most attractive azathioprine market?

The most attractive opportunities are likely to be transplant-heavy markets, government procurement channels, and regions where biologic access is restricted and reliable low-cost immunosuppression is valued.

References

1. Clinical Pharmacogenetics Implementation Consortium. (2018). Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes. Clinical Pharmacology & Therapeutics, 103(2), 242-252. https://cpicpgx.org/guidelines/guideline-for-thiopurines-based-on-tpmt-and-nudt15-genotypes/

2. U.S. Food and Drug Administration. (2024). Azathioprine prescribing information. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. National Library of Medicine. (2024). Azathioprine drug information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

5. World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: Azathioprine. https://www.whocc.no/atc_ddd_index/